Work

Exploring the role and clinical implications of proteasome inhibition in medulloblastoma

Year: 2021

Type: review

Abstract: Ubiquitin proteasome-mediated protein degradation has been implicated in posttranslational oncogenesis in medulloblastoma. Current research is evaluating the clinical implications of proteasome inhibition as a therapeutic target. In medulloblastoma cell lines, proteasome inhibitors induce apoptosis and inhibit cell proliferation via multiple pathways involving activation of caspase pathways, NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway inhibition, reduced AKT/mTOR pathway activity, and pro-apoptotic protein expression. Second-generation proteasome inhibitors demonstrate blood-brain barrier penetration while maintaining antitumor effect. This review summarizes the ubiquitin-proteasome system in the pathogenesis of medulloblastoma and the potential clinical implications.

Source: Pediatric Blood & Cancer

DOI: 10.1002/pbc.29168

Authors: Clay M. Hoerig, Ashley S. Plant‐Fox, Michelle D. Pulley, Kaijun Di, Daniela A. Bota

Institutions: Children's Hospital of Orange County, University of California, Irvine, Lurie Children's Hospital

Language: English

Topic: Ubiquitin and proteasome pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute